Quitting smoking is not a willpower problem. Nicotine physically rewires the brain's reward circuitry, elevating dopamine and creating a dependency that willpower alone cannot override. After weeks of quitting attempts, the withdrawal symptoms, cravings, and irritability force most smokers back to cigarettes. The neurobiology is real. The problem demands a neurobiological solution.
Bupropion works by directly targeting the neural pathways nicotine hijacks. It raises dopamine and norepinephrine levels in the reward centers, reducing the intensity of cravings and the physical withdrawal symptoms that make quitting so difficult. The result: a realistic chance to break the cycle.
Prescribed under the brand name Zyban, bupropion is FDA-approved specifically for smoking cessation. It is taken for 7 to 12 weeks surrounding your quit date, with the goal of sustained freedom from smoking.
Includes ongoing provider care & support
Platform access & educational content
Smoking cessation without treatment has dismal long-term success rates. These numbers show why bupropion makes such a measurable difference.
Bupropion SR 150mg is FDA-approved for smoking cessation under brand name Zyban. Individual quit success rates vary based on dosing consistency, behavioral support, and patient factors. Results are not guaranteed.
Bupropion's therapeutic effect rests on three distinct pharmacological mechanisms that address the neurobiology of tobacco dependence.
Bupropion blocks the reabsorption of dopamine and norepinephrine at the synapse, raising their concentrations in reward and motivation circuits. Nicotine produces its addictive effect by triggering dopamine release. By maintaining higher baseline dopamine levels, bupropion counteracts the withdrawal-related dopamine deficit that drives cravings.
Bupropion partially antagonizes nicotinic acetylcholine receptors, the same receptors nicotine binds to in the brain. This dual action means that even if you slip and smoke a cigarette, the rewarding effect is blunted; nicotine cannot produce its normal dopamine surge because the receptors are partially blocked by bupropion.
The irritability, restlessness, difficulty concentrating, and dysphoria that characterize nicotine withdrawal stem from acute dopamine and norepinephrine depletion. By raising these neurotransmitters, bupropion reduces the intensity and duration of withdrawal symptoms, making the critical first weeks of quitting physiologically tolerable.
Bupropion is most effective when taken within a structured protocol that spans several weeks. Here is how the treatment unfolds.
Start bupropion approximately one week before your target quit date. Your provider will prescribe a typical starting dose of 150mg once daily for the first three days, then increase to 150mg twice daily (total 300mg daily). You continue smoking during this phase. The medication is building up in your bloodstream and beginning to normalize dopamine and norepinephrine levels.
On your predetermined quit date, you stop smoking completely while continuing bupropion at the prescribed dose. The first 2-6 weeks are the most difficult; withdrawal peaks around day 3-5. Bupropion reduces craving intensity and withdrawal severity during this critical window. Many patients report that the medication makes this period physiologically tolerable in a way that prior quit attempts were not.
Continue bupropion as prescribed. By week 6, the worst of withdrawal has passed. Remaining cravings are typically situational rather than constant. Bupropion continues to provide relapse protection. Treatment is usually continued for 7 to 12 weeks total, though some patients benefit from extended use up to 6 months to solidify smoke-free status.
Bupropion is most effective when paired with behavioral counseling, group support programs, or habit replacement strategies. Your Obsidian Genetics provider can recommend evidence-based behavioral resources. The medication handles the neurochemistry; behavioral support handles the learned patterns and environmental triggers.
Bupropion works best when you understand the timeline and what each phase feels like.
Start bupropion. Still smoking. You may experience mild side effects like dry mouth, insomnia, or slight anxiety as the medication begins to affect dopamine and norepinephrine. These typically resolve within a few days. Medication is building in your system.
Stop smoking on your predetermined quit date. Bupropion is now working to reduce withdrawal. You will likely experience cravings, irritability, and difficulty concentrating; this is normal and expected. The cravings are present but less overwhelming than in unaided quit attempts. Stay with it.
The most difficult phase. Withdrawal intensity peaks and then gradually declines. Most patients find that cravings become periodic rather than constant by week 4-5. Bupropion significantly reduces the urge to smoke compared to placebo. Sleep may improve; irritability begins to ease.
Nicotine dependence is fading. Remaining cravings are triggered by specific situations, not withdrawal. Many patients report freedom from constant cravings and dramatically reduced urge to smoke. Bupropion continues to provide relapse protection. Long-term abstinence becomes the new normal.
Bupropion is safe and well-tolerated for most patients. Certain conditions require careful screening.
Most frequently reported: dry mouth, insomnia or sleep disruption, headache, nausea, dizziness, and constipation. These typically appear in the first 1-2 weeks and often resolve with continued use. Doses in the afternoon or early evening can help with insomnia. Staying hydrated helps with dry mouth.
Bupropion lowers the seizure threshold in a dose-dependent manner. This is the most important safety consideration. It is contraindicated in patients with a history of seizure disorder, eating disorders (anorexia or bulimia), or those experiencing abrupt alcohol or benzodiazepine withdrawal. Your provider will screen for these conditions during intake.
Like all antidepressant medications, bupropion carries an FDA black box warning for increased suicidal ideation, particularly in patients under 25. Your provider monitors for mood changes, especially in the first weeks of treatment. If you experience mood worsening or suicidal thoughts, contact your provider immediately.
Bupropion is contraindicated in patients with seizure disorder, current or prior eating disorders, or those stopping alcohol or benzodiazepines. It should not be combined with MAOIs. Alcohol use should be avoided or minimized, as it lowers seizure threshold further. If you have a personal or family history of bipolar disorder, discuss this with your provider before starting. All prescriptions are issued following a thorough clinical intake by a licensed provider.
Pricing
One flat rate. Physician supervision, compounded medication, and ongoing support included.
Month-to-month. Full flexibility.
$43/mo · Save $18 vs monthly.
$39/mo · Save $60 vs monthly.
$34/mo · Save $180 vs monthly.
Includes: physician consultation · ongoing provider support · free shipping
FDA Approval Status: Bupropion SR 150mg (extended-release) is FDA-approved for smoking cessation under the brand name Zyban. This is a standard generic medication manufactured to FDA standards. Obsidian Genetics prescribes the established, proven formulation approved for this indication. This is not an off-label use or compounded preparation.
Black Box Warning: Bupropion carries an FDA black box warning for increased suicidal ideation, particularly in patients under 25. Your provider will screen for neuropsychiatric risk during your intake and monitor you throughout treatment. If you experience suicidal thoughts, mood worsening, or behavioral changes, contact your provider or emergency services immediately.
Not Medical Advice: The content on this page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before starting any new treatment. All Obsidian Genetics prescriptions are issued following a clinical review by a licensed provider.
Citations & Evidence: Cardiovascular risk from smoking: CDC, WHO epidemiological data. Bupropion efficacy: Hurt RD et al., N Engl J Med. 1997;337(17):1195-1202. This landmark randomized controlled trial established the approximate doubling of quit rates with bupropion versus placebo. Baseline quit rate data: CDC SmokingCessation.gov, national smoking cessation statistics.
Obsidian Genetics is a telehealth platform connecting patients with licensed providers. All prescriptions are issued by state-licensed healthcare providers. ©2024 Obsidian Genetics. All rights reserved.